Don’t miss the latest developments in business and finance.

Alembic Pharmaceuticals receives USFDA approval for Doxycycline Hyclate Tablets

Image
Capital Market
Last Updated : May 15 2020 | 12:31 PM IST
Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Doxycycline Hyclate Tablets USP 100mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Vibra-Tabs, 100mg of Pfizer, Inc. Doxycycline Hyclate Tablets USP 100mg should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Doxycycline Hyclate Tablets 100mg have an estimated market size of US$ 53 million for twelve months ending December 2019 according to IQVIA.

Powered by Capital Market - Live News

Also Read

First Published: May 15 2020 | 11:33 AM IST

Next Story